Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine and Probiotics for Mild-Moderate COVID-19
NCT05911022Completed
- Sponsor
- Ain Shams University
- Start
- Jul 2021
- Primary completion
- Aug 2022
- Modality
- Nucleic Acid-Directed Small Molecules, Live Biotherapeutic Products, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of colchicine and lactobacillus acidophilus in coronavirus disease 2019 (COVID-19), sponsored by Ain Shams University. Started Jul 2021; status: completed.
02
Drugs
colchicinelactobacillus acidophilus
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05911022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05911022.